These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9689806)

  • 1. The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Betta PG
    Monaldi Arch Chest Dis; 1998 Apr; 53(2):186-7. PubMed ID: 9689806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
    Galateau-Salle F
    Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Suster S; Moran CA
    Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
    Betta PG; Magnani C; Bensi T; Trincheri NF; Orecchia S
    Arch Pathol Lab Med; 2012 Mar; 136(3):253-61. PubMed ID: 22372901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
    Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
    Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelioma as a risk indicator of asbestos exposure: the role of the pathologist.
    Zampi G; Comin CE; Dini S
    Med Lav; 1995; 86(5):389-92. PubMed ID: 8684289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems in mesothelioma diagnosis.
    Addis B; Roche H
    Histopathology; 2009 Jan; 54(1):55-68. PubMed ID: 19054156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma.
    Marchevsky AM; Wick MR
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):140-4. PubMed ID: 17525624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mesothelioma and mesothelial hyperplasia].
    Li LY; Luo WC; Zhu YJ
    Zhonghua Nei Ke Za Zhi; 1990 Jun; 29(6):328-31, 381. PubMed ID: 2269029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.
    Kao SC; Griggs K; Lee K; Armstrong N; Clarke S; Vardy J; van Zandwijk N; Burn J; McCaughan BC; Henderson DW; Klebe S
    Pathology; 2011 Jun; 43(4):313-7. PubMed ID: 21532523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.
    Donna A; Betta PG; Chiodera P; Bellingeri D; Libener R; Zorzi F; Tassi GF
    Hum Pathol; 1997 Aug; 28(8):929-37. PubMed ID: 9269829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.
    Mlika M; Lamzibri O; Bacha S; Laabidi S; Haddouchi C; Mezni FE
    J Immunoassay Immunochem; 2018; 39(3):263-273. PubMed ID: 29757709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
    Rakha EA; Patil S; Abdulla K; Abdulkader M; Chaudry Z; Soomro IN
    Diagn Cytopathol; 2010 Dec; 38(12):874-9. PubMed ID: 20049969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.